Avekshan is developing AVK 001, a Fixed Dose Combination (FDC) of methylphenidate [MPH] hydrochloride and naltrexone [NTX] hydrochloride for the treatment of ADHD.
MPH hydrochloride is a mild central nervous system (CNS) stimulant indicated as an integral part of a total treatment program (typically including other psychological, educational, and social remedial measures) for a stabilizing effect in children and adults with attention deficit hyperactivity disorder (ADHD).
Naltrexone hydrochloride is an opioid antagonist that markedly or completely, though reversibly, blocks the subjective effects of intravenously administered opioids. It is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids.